Jesup & Lamont Downgrades Luminex (LMNX) to Neutral
More News related to LMNX
- JPMorgan Starts Luminex (LMNX) at Neutral
- Luminex Corporation Second Quarter Earnings Release Scheduled for August 7, 2008
- Luminex Corporation and ViroNovative Announce License Agreement for Human Metapneumovirus Rights
- Luminex Corporation Announces Closing of Public Offering of Common Stock and Exercise of Over-Allotment Option
- Luminex (LMNX) Prices 3.5 Million Share Offering
More News related to Downgrades
- Matrix USA Rating Changes 7/18
- Piper Jaffray Downgrades Infinity Property and Casualty (IPCC) To Neutral
- Stanford Downgrades ViroPharma (VPHM) to Hold
- SemGroup Energy (SGLP) Gets Cut In Half
- Stanford Downgrades ValueClick (VCLK) to Hold
Jesup & Lamont downgrades Luminex (Nasdaq: LMNX) from Buy to Neutral, as the stock reached its $20 price target.
The firm points out that shares of Luminex are up more than 50% over the last year, spiking earlier this year on "speculation regarding takeover targets of a new, much heralded $350 million blank check IPO from Goldman Sachs, Liberty Lane."
Jesup & Lamont details Luminex's "limited history of profitability and acquisitions", its dependence on "outside manufacturers" and a reliance on "regulatory agencies" as potential risks.
Luminex Corporation develops, manufactures, and sells proprietary biological testing technologies and products for applications in the life sciences industry.
Related Categories
DowngradesStocks Mentioned
-0.31Related Entities
Sign up for StreetInsider Free!
Recieve full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
